Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa

Pediatric Infectious Disease Journal

Volumn 30, Issue 11, 2011, Pages 974-979

  Meyers, Tammy M ^a   Yotebieng, Marcel ^b   Kuhn, Louise ^c,d   Moultrie, Harry ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b IL   (United States)

^c Vagelos College of Physicians and Surgeons   (United States)

^d Department of Medicine   (United States)

Author keywords

children; HIV treatment outcomes; South Africa

Indexed keywords

EFAVIRENZ; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LOPINAVIR PLUS RITONAVIR;

ADOLESCENT; ARTICLE; CHILD; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTPATIENT; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOUTH AFRICA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD;

EID: 80054980206     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31822539f6     Document Type: Article

References (34)

1. UNAIDS. AIDS epidemic update. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2007.
2. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva, Switzerland: WHO; 2010.
3. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach (2010 revision). Geneva, Switzerland: WHO; 2010.
4. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363: 1510-1520.
5. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489. (Pubitemid 352005822)
6. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009;49:1915-1927.
7. WHO. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Recommendations for a public health approach (2005 revision). Geneva, Switzerland: World Health Organisation; 2005.
8. Meyers T, Eley B, Leoning W. Guidelines for the Management of HIVInfected Children-2005, Health. 1st ed. Pretoria, South Africa: Jacana Media; 2005.
9. Department of Health, South Africa. Guidelines for the Management of HIV infected Children. South Africa: Department of Health; 2005.
10. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:1553-1560. (Pubitemid 38544359)
11. Glencross D, Scott LE, Jani IV, et al. CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4-T-cell enumeration. Cytometry. 2002;50:69-77.
12. CDC. A SAS program for CDC growth charts. Center for Disease Control and Prevention; 2000-Updated May 22, 2007]. Available at: http://www. cdc.gov/NCCDPHP/dnpa/growthcharts/resources/sas.htm. Accessed December 31, 2008.
13. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weightfor-height, and body mass index-for-age: methods and development. Geneva, Switzerland: WHO; 2006.
14. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899. (Pubitemid 350005233)
15. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793. (Pubitemid 44223102)
16. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20:2355-2360. (Pubitemid 44789538)
17. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med. 1997;16:2349-2380. (Pubitemid 27458250)
18. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557-572.
19. Davies MA, Keiser O, Technau K, et al. Outcomes of the South African National Antiretroviral Treatment programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:730-737.
20. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
21. Eley B, Davies MA, Apolles P, et al. Antiretroviral treatment for children. S Afr Med J. 2006;96(9 pt 2):988-993.
22. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a pediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.
23. Gibb DM, Goodall RL, Giacomet V, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J. 2003;22:56-62. (Pubitemid 36091779)
24. WHO. Global tuberculosis control 2010. Geneva, Switzerland: WHO; 2010.
25. Vishnuvardhan D, Moltke LL, Richert C. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003;17: 1092-1094. (Pubitemid 36549726)
26. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224. (Pubitemid 28553744)
27. Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3336-3342. (Pubitemid 44527507)
28. Burton ME, Shaw LM, Schentag JJ, et al. Applied Pharmacokinetics and Pharmakodynamics: Principles of Therapeutic Drug Monitoring. 4th ed. Lippincott Williams and Wilkins; 2005.
29. La Porte CJ CE, Bertz R. Pharmacokinetics of adjusted-dose lopinavirritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:1553-1560. (Pubitemid 38544359)
30. McIlleron H, Ren Y, Nuttall J, et al, eds. Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicinbased anti-TB treatment. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, QC, Canada.
31. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14:1039-1043.
32. Frohoff C, Moodley M, Fairlie L, et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011;6:e17273.
33. Muller AD, Myer L, Jaspan H. Virologic suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy. Clin Infect Dis. 2009;48:e3-e5.
34. Yotebieng M, Van Rie A, Moultrie H, et al. Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. AIDS. 2010;24:139-146.